A 1,079 crore market cap co. in the pharma industry manufacturing bulk drugs for Macrolides and Anti-TB products in India, besides being a major player in Anti-Bacterial, Anti-Malarial, and Corticosteroids.
Future outlook - Planned capex of 5 cr. for capacity enhancement in FY24. This will help them reach target growth rate of 15-20%.
Debt-free, consistent and rather increasing OPM in the range of 10%-15% since 2012 with a healthy balance sheet with a strong promoters holding of approx. 70% with public holding the rest 30%. Since the company is a microcap, there is no coverage of institutions yet, which makes it a future "on radar" company for big players like MFs, AIFs, etc.
On the technical front, the monthly chart looks promising with rising OBV and volume accumulation with price sustaining above the trendline. Even though the March monthly candle still needs to be close above the trendline, it should be on the watchlist for a close above the trendline to start it's journey towards being a dark horse for the pharma industry!
Disc: We are not SEBI registered. Please do your own due diligence and seek advice from your financial advisor. No buy or sell recommendation.
Future outlook - Planned capex of 5 cr. for capacity enhancement in FY24. This will help them reach target growth rate of 15-20%.
Debt-free, consistent and rather increasing OPM in the range of 10%-15% since 2012 with a healthy balance sheet with a strong promoters holding of approx. 70% with public holding the rest 30%. Since the company is a microcap, there is no coverage of institutions yet, which makes it a future "on radar" company for big players like MFs, AIFs, etc.
On the technical front, the monthly chart looks promising with rising OBV and volume accumulation with price sustaining above the trendline. Even though the March monthly candle still needs to be close above the trendline, it should be on the watchlist for a close above the trendline to start it's journey towards being a dark horse for the pharma industry!
Disc: We are not SEBI registered. Please do your own due diligence and seek advice from your financial advisor. No buy or sell recommendation.